Could a transplant drug keep a rare airway disease at bay?
NCT ID NCT05153668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested whether the immunosuppressant drug everolimus could help people with idiopathic subglottic stenosis, a rare condition where scarring narrows the airway. Eight participants took everolimus for 42 days after a dilation surgery to open the airway. The goal was to see if the drug could lengthen the time between repeat surgeries, which are often needed to keep the airway open.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Everolimus (an immunosuppressant drug)
- What this could lead to
- If successful, this could lead to the first FDA-approved drug treatment for idiopathic subglottic stenosis, potentially reducing the need for repeat surgeries.
- What could go wrong
- This is a very early, small proof-of-concept study with only 8 participants. The drug is an immunosuppressant, which carries risks like infection, and it may not prove effective in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC SUBGLOTTIC TRACHEAL STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Outpatient Center
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.